Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
Lebwohl M, Strober B, Schrader A, Li A, Eckmann T, Zhu B, Malatestinic W, Birt J, Feely M, Blauvelt A. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs - Real World Outcomes 2024, 11: 451-464. PMID: 38914857, PMCID: PMC11365873, DOI: 10.1007/s40801-024-00439-w.Peer-Reviewed Original ResearchTumor necrosis factor inhibitorsInvestigator's Global AssessmentEffectiveness of ixekizumabDermatology Life Quality IndexDermatology Life Quality Index 0/1Body surface areaIL-23iCorEvitas Psoriasis RegistryIL-12/23iPatient-reported outcomesIL-17iPsoriasis RegistryBiologic therapySkin painSwitching to ixekizumabIL-23 inhibitorsDisease severityInterleukin-23 inhibitorAdjusted mean changesMultivariable modified Poisson regressionInterleukin-12/23 inhibitorsFollow-up visitConfidence intervalsModified Poisson regressionReal-world study